




- (51) **International Patent Classification:**
A61K 31/35 (2006.01) C12Q 1/68 (2006.01)
A61K 31/357 (2006.01)
- (21) **International Application Number:**
PCT/US2015/032684
- (22) **International Filing Date:**
27 May 2015 (27.05.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/003,937 28 May 2014 (28.05.2014) US
- (71) **Applicant: EISAI R&D MANAGEMENT CO., LTD**
[JP/JP]; 6-10, Koishikawa 4-chome, Tokyo, 112-8088 (JP).
- (72) **Inventor; and**
- (71) **Applicant (for US only): LITTLEFIELD, Bruce, A.**
[US/US]; 4 Twin Brooks Circle, Andover, MA 01810 (US).
- (72) **Inventors: ASANO, Makoto;** C/o Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 300-2635 (JP). **MATSUI, Junji;** 5-9-33 Matsushiro, Tsukuba, Ibaraki, 305-0035 (JP). **OLIVO, Martin;** 21st Avenue, Westwood, NJ 07675 (US). **OZAWA, Yoichi;** C/o Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai Tsukuba-shi, Ibaraki, 300-2635 (JP). **YU, Yanke;** 278 Lowell Street, Lexington, MA 02420 (US).
- (74) **Agent: MICHAUD, Susan, M.;** Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) **Title:** USE OF ERIBULIN IN THE TREATMENT OF CANCER**Fig. 1**

**: P<0.01 by student's t-test

(57) **Abstract:** The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.

Published:

— *with international search report (Art. 21(3))*